I am a
Home I AM A Search Login

Papers of the Week

2021 Mar 18

Oncol Res Treat

Seizures and Neuropsychiatric Toxicity in Patients with Non-Metastatic CRPC Treated with New Antiandrogens: Systematic Review and Meta-Analysis.


Sopeña Sutil R, Silva Ruiz J, Garcia Gomez B, Romero-Otero J, Garcia-Gonzalez L, Duarte Ojeda J M, de Velasco G, Castellano Gauna D, Rodriguez Antolin A
Oncol Res Treat. 2021 Mar 18:1-8.
PMID: 33735902.


Recently, enzalutamide, apalutamide, and darolutamide have shown benefits in metastasis-free survival in non-metastatic castration-resistant prostate cancer (nmCRPC) patients compared to placebo. Previous evidence about the safety profile of these new androgens is limited. This meta-analysis studies seizure and neuropsychiatric effects of new anti-androgens compared to placebo in nmCRPC patients.